Biopharma Co. Hit With Investor Action Over COVID Treatment
Eiger BioPharmaceuticals Inc. was hit with a proposed class action in California federal court on Tuesday by an investor who claims the company overstated the likelihood that its experimental treatment for...To view the full article, register now.
Already a subscriber? Click here to view full article